Search PubMed⌕ Search

PubMed · 16100539

[Cerebral cavernous malformations].

Abstract

BACKGROUND: Cerebral cavernous malformations exist in sporadic and familial forms. They have considerable genetic and clinical heterogeneity. Better understanding of these disorders may improve management. MATERIAL AND METHODS: This review is based on personal experience and recent literature. RESULTS: Cerebral cavernous malformations are venous malformations that can be detected with gradient echo MRI of the brain. Approximately 0.5% of the general population have the sporadic form with a single or a few cerebral cavernous malformations which mostly are asymptomatic. Those with the familial form usually have several cavernous malformations caused by an autosomal dominant condition. So far, 3 loci have been identified: CCM1 on chromosome 7q, CCM2 on chromosome 7p, and CCM3 on chromosome 3q, occurring in, respectively, approximately 40%, 20% and 40% of the families. CCM1 is caused by a mutation in the KRIT1 gene and CCM2 is caused by a mutation in the MGC4607 gene, while the gene for CCM3 is not yet identified. Mean age at onset is 20-40, but onset can occur at all ages. The most frequent symptoms are seizures, cerebral haemorrhage, chronic headache and focal neurological deficits. Many carriers are, however, asymptomatic. INTERPRETATION: Sporadic cerebral cavernous malformation is often asymptomatic, while the familial form shows phenotypic and genetic heterogeneity. The symptoms are depending on the location of the malformations as well as whether haemorrhage does occur.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Jeanette Koht, Geir J Braathen, Dirk Neubert, Michael Bjørn Russell. 2005-08-11. [Cerebral cavernous malformations].. https://pubmed.ncbi.nlm.nih.gov/16100539/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Stereotactic fractionated radiotherapy for recurrent capillary hemangioma of the cavernous sinus.

BACKGROUND AND PURPOSE: Capillary hemangioma of the cavernous sinus is a rare benign skull base tumor that can successfully be treated with radiotherapy. Due to its location, both the tumor itself and the treatment might cause significant functional deficits. Therefore, the different treatment options should be discussed with the patients. CASE REPORT: A case of successful stereotactic fractionated radiotherapy (SFRT) performed after multiple recurrences is described. A 62-year-old male patient with a hemangioma of the right cavernous sinus, orbita and suprasellar region who had previously undergone three surgical procedures received postoperative SFRT for the residual tumor (target volume 85 cm3, Figure 1). SFRT was administered 5 months after surgery with single daily fractions of 2 Gy to a total dose of 40 Gy. RESULTS: No acute or late toxicity of SFRT was observed. Symptomatic improvement was evident 6 months after SFRT. Imaging over a 20-month period showed a continuous and pronounced decrease in residual tumor size (Figure 2). CONCLUSION: Postoperative SFRT with moderate doses is well tolerated and might induce both symptomatic and radiologic improvement of large capillary hemangioma.

Cavernous Sinus↗

[Inflammatory presentation of a cavernous dural fistula: diagnosis with color and pulse Doppler imaging].

We report a case of a cavernous dural fistula in a 54-year-old man the source of inflammatory ocular symptoms. Poorly adapted treatment with corticosteroids led to iatrogenic complications. We will attempt to show the advantage of color Doppler imaging for the diagnosis of this infrequent lesion. The only indication of digitalized angiography is for endovascular treatment.

Cavernous Sinus↗

Peripheral primitive neuroectodermal tumor of the cavernous sinus: case report.

OBJECTIVE: Ewing sarcoma/peripheral primitive neuroectodermal tumors (pPNET family) are small, round, blue cell tumors that have a decided predilection for young patients and commonly arise in bone and soft tissue. We are reporting a rare case of cavernous sinus pPNET in a 48-year-old woman. CLINICAL PRESENTATION: A 48-year-old woman presented with headache, ipsilateral maxillary, and ophthalmic and oculomotor nerve palsies. Neuroimaging revealed a cavernous sinus lesion. INTERVENTION: The patient underwent debulking of the tumor, and the diagnosis of a pPNET was made based on histological, immunohistochemical, and molecular genetics (EWS-FLI1 fusion gene) findings. Bone scans, bone marrow aspiration, and biopsy and chest computed tomographic scans showed no evidence of systemic involvement. The patient had adjuvant treatment with radiotherapy and chemotherapy. After 14 months, the patient had no neurological deficits, and neuroimaging showed stable disease, although some chemotherapy complications occurred. CONCLUSION: This is a case of cavernous sinus pPNET in a 48-year-old woman, in whom the diagnosis is supported by the presence of EWS-FLI1 fusion gene. This seems to be the first reported case of a cavernous sinus pPNET confirmed by molecular genetic analysis.

Cavernous Sinus↗